TapewireFind a company

person · Reporting owner

Reumuth Mary

Disclosed activity across 1 company

Tapewire entity
73971
SEC CIK
0001710969

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
KALA BIO, Inc.KALA · Entity 7964CHIEF FINANCIAL OFFICEROctober 22, 2025October 24, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

KALA BIO, Inc.

Report date October 22, 2025 · Filed October 24, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect28,906 Last balance in matching sequence After 2025-10-23 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2025-10-22 · Sale · Disposed 32,230 · Balance 29,873

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2: Includes 28,906 unvested RSUs.

Row 2 · 2025-10-23 · Sale · Disposed 967 · Balance 28,906

F2: Includes 28,906 unvested RSUs.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2: Includes 28,906 unvested RSUs.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 23, 2025 Filed Oct 24, 2025 20:00 UTC KALA BIO, Inc. KALA · Entity 7964 SaleCommon Stock 967 $0.82 $792.94
Disclosure

SEC source: 0001710969-25-000003 · form4-10242025_081007.xml · nonDerivative · entry 2

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,906

F2 · balance_after: Includes 28,906 unvested RSUs.

Read SEC document
October 22, 2025 Filed Oct 24, 2025 20:00 UTC KALA BIO, Inc. KALA · Entity 7964 SaleCommon Stock 32,230 $0.83 $26,750.90
Disclosure

SEC source: 0001710969-25-000003 · form4-10242025_081007.xml · nonDerivative · entry 1

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,873

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2 · balance_after: Includes 28,906 unvested RSUs.

Read SEC document
June 24, 2025 Filed Jun 26, 2025 20:00 UTC KALA BIO, Inc. KALA · Entity 7964 SaleCommon Stock 3,631 $4.01 $14,560.31
Disclosure

SEC source: 0001415889-25-018320 · form4-06262025_080607.xml · nonDerivative · entry 1

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,100

F1 · shares: This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on June 22, 2023.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.87 to $4.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F3 · balance_after: Includes 28,906 unvested RSUs.

Read SEC document
June 03, 2025 Filed Jun 4, 2025 20:00 UTC KALA BIO, Inc. KALA · Entity 7964 SaleCommon Stock 2,850 $3.74 $10,659.00
Disclosure

SEC source: 0001415889-25-015680 · form4-06042025_080607.xml · nonDerivative · entry 1

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,731

F1 · shares: This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on May 31, 2023.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F3 · balance_after: Includes 40,953 unvested RSUs.

Read SEC document
January 06, 2025 Filed Jan 7, 2025 20:12 UTC KALA BIO, Inc. KALA · Entity 7964 GrantStock Option (right to buy) · Derivative 45,200 $0.00 Strike: $7.53 $0.00
Disclosure

SEC source: 0001415889-25-001059 · form4-01082025_010125.xml · derivative · entry 3

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,200

Underlying: Common Stock · 45,200 shares

Expires 2035-01-05

F5 · derivative.exercise_date: This option was granted on January 6, 2025 and vests over four years beginning on the vesting commencement date of January 6, 2025, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 6, 2029, subject to the Reporting Person's continued employment with the Issuer.

Read SEC document
January 06, 2025 Filed Jan 7, 2025 20:12 UTC KALA BIO, Inc. KALA · Entity 7964 SaleCommon Stock 1,706 $7.63 $13,016.78
Disclosure

SEC source: 0001415889-25-001059 · form4-01082025_010125.xml · nonDerivative · entry 2

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,581

F3 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2024.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.48 to $7.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2 · balance_after: Includes 49,523 unvested RSUs.

Read SEC document
January 06, 2025 Filed Jan 7, 2025 20:12 UTC KALA BIO, Inc. KALA · Entity 7964 GrantCommon Stock 10,100 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-001059 · form4-01082025_010125.xml · nonDerivative · entry 1

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,287

F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 6, 2026, as to 1/3 of the shares underlying the RSUs on January 6, 2027 and as to the final 1/3 of shares underlying the RSUs on January 6, 2028.

F2 · balance_after: Includes 49,523 unvested RSUs.

Read SEC document
June 26, 2024 Filed Jun 27, 2024 20:00 UTC KALA BIO, Inc. KALA · Entity 7964 SaleCommon Stock 4,163 $4.75 $19,774.25
Disclosure

SEC source: 0001415889-24-018375 · form4-06272024_080606.xml · nonDerivative · entry 1

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,187

F1 · shares: This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on June 22, 2023.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $5.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F3 · balance_after: Includes 44,131 unvested RSUs.

Read SEC document
May 31, 2024 Filed Jun 3, 2024 20:00 UTC KALA BIO, Inc. KALA · Entity 7964 SaleCommon Stock 1,786 $6.09 $10,876.74
Disclosure

SEC source: 0001415889-24-015224 · form4-06032024_080608.xml · nonDerivative · entry 1

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,350

F1 · shares: This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on May 31, 2023.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F3 · balance_after: Includes 56,177 unvested RSUs.

Read SEC document
January 04, 2024 Filed Jan 5, 2024 16:04 UTC KALA BIO, Inc. KALA · Entity 7964 GrantStock Option (right to buy) · Derivative 20,500 $0.00 Strike: $7.00 $0.00
Disclosure

SEC source: 0001415889-24-000767 · form4-01052024_090154.xml · derivative · entry 3

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,500

Underlying: Common Stock · 20,500 shares

Expires 2034-01-03

F6 · derivative.exercise_date: This option was granted on January 4, 2024 and vests over four years beginning on the vesting commencement date of January 4, 2024, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 4, 2028, subject to the Reporting Person's continued employment with the Issuer.

Read SEC document
January 04, 2024 Filed Jan 5, 2024 16:04 UTC KALA BIO, Inc. KALA · Entity 7964 SaleCommon Stock 1,227 $6.74 $8,269.98
Disclosure

SEC source: 0001415889-24-000767 · form4-01052024_090154.xml · nonDerivative · entry 2

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,136

F3 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2021.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.73 to $6.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F5 · balance_after: Includes 61,831 unvested RSUs.

Read SEC document
January 04, 2024 Filed Jan 5, 2024 16:04 UTC KALA BIO, Inc. KALA · Entity 7964 GrantCommon Stock 4,600 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-000767 · form4-01052024_090154.xml · nonDerivative · entry 1

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,363

F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2025, as to 1/3 of the shares underlying the RSUs on January 4, 2026 and as to the final 1/3 of shares underlying the RSUs on January 4, 2027.

F2 · balance_after: Includes 65,156 unvested RSUs.

Read SEC document
June 22, 2023 Filed Jun 23, 2023 20:00 UTC KALA BIO, Inc. KALA · Entity 7964 GrantStock Option (right to buy) · Derivative 48,192 $0.00 Strike: $14.56 $0.00
Disclosure

SEC source: 0001415889-23-010285 · form4-06232023_080610.xml · derivative · entry 2

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,192

Underlying: Common Stock · 48,192 shares

Expires 2033-06-21

F3 · derivative.exercise_date: This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter.

Read SEC document
June 22, 2023 Filed Jun 23, 2023 20:00 UTC KALA BIO, Inc. KALA · Entity 7964 GrantCommon Stock 36,144 $0.00 $0.00
Disclosure

SEC source: 0001415889-23-010285 · form4-06232023_080610.xml · nonDerivative · entry 1

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,763

F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026.

F2 · balance_after: Includes 60,556 unvested RSUs.

Read SEC document
May 31, 2023 Filed Jun 2, 2023 20:00 UTC KALA BIO, Inc. KALA · Entity 7964 Disposition to issuerStock Option (right to buy) · Derivative 648 Not disclosed Strike: $68.50 Not disclosed
Disclosure

SEC source: 0001415889-23-009136 · form4-06022023_080614.xml · derivative · entry 9

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 648 shares

Expires 2032-01-03

F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 11,313 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 3,423 RSUs that vest over three years, with 85% of such RSUs vesting on May 31, 2025 and 15% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock.

F11 · derivative.exercise_date: The canceled option was granted on January 3, 2022 and provided for the purchase of up to 1,620 shares of common stock of the issuer based on the level of achievement of specified performance metrics relating to financial, operational and scientific matters, of which, prior to the option exchange program, options to purchase 432 shares had vested, options to purchase 864 shares had been forfeited and options to purchase up to 324 shares were unvested assuming maximum level of achievement (options to purchase 216 shares were unvested assuming target level of achievement). The vested portion of the option and the unvested portion of the option assuming target level of achievement were eligible for the issuer's option exchange program.

F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

Read SEC document
May 31, 2023 Filed Jun 2, 2023 20:00 UTC KALA BIO, Inc. KALA · Entity 7964 Disposition to issuerStock Option (right to buy) · Derivative 3,059 Not disclosed Strike: $68.50 Not disclosed
Disclosure

SEC source: 0001415889-23-009136 · form4-06022023_080614.xml · derivative · entry 8

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,059 shares

Expires 2032-01-03

F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 11,313 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 3,423 RSUs that vest over three years, with 85% of such RSUs vesting on May 31, 2025 and 15% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock.

F10 · derivative.exercise_date: The canceled option was granted on January 3, 2022 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.

F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

Read SEC document
May 31, 2023 Filed Jun 2, 2023 20:00 UTC KALA BIO, Inc. KALA · Entity 7964 Disposition to issuerStock Option (right to buy) · Derivative 1,813 Not disclosed Strike: $343.00 Not disclosed
Disclosure

SEC source: 0001415889-23-009136 · form4-06022023_080614.xml · derivative · entry 7

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,813 shares

Expires 2031-01-03

F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 11,313 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 3,423 RSUs that vest over three years, with 85% of such RSUs vesting on May 31, 2025 and 15% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock.

F9 · derivative.exercise_date: The canceled option was granted on January 4, 2021 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.

F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

Read SEC document
May 31, 2023 Filed Jun 2, 2023 20:00 UTC KALA BIO, Inc. KALA · Entity 7964 Disposition to issuerStock Option (right to buy) · Derivative 2,399 Not disclosed Strike: $192.00 Not disclosed
Disclosure

SEC source: 0001415889-23-009136 · form4-06022023_080614.xml · derivative · entry 6

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,399 shares

Expires 2030-01-01

F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 11,313 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 3,423 RSUs that vest over three years, with 85% of such RSUs vesting on May 31, 2025 and 15% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock.

F8 · derivative.exercise_date: The canceled option was granted on January 2, 2020 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.

F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

Read SEC document
May 31, 2023 Filed Jun 2, 2023 20:00 UTC KALA BIO, Inc. KALA · Entity 7964 Disposition to issuerStock Option (right to buy) · Derivative 2,999 Not disclosed Strike: $259.50 Not disclosed
Disclosure

SEC source: 0001415889-23-009136 · form4-06022023_080614.xml · derivative · entry 5

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,999 shares

Expires 2029-01-01

F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 11,313 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 3,423 RSUs that vest over three years, with 85% of such RSUs vesting on May 31, 2025 and 15% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock.

F7 · derivative.exercise_date: The canceled option was granted on January 2, 2019 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.

F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

Read SEC document
May 31, 2023 Filed Jun 2, 2023 20:00 UTC KALA BIO, Inc. KALA · Entity 7964 Disposition to issuerStock Option (right to buy) · Derivative 1,399 Not disclosed Strike: $643.00 Not disclosed
Disclosure

SEC source: 0001415889-23-009136 · form4-06022023_080614.xml · derivative · entry 4

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,399 shares

Expires 2028-02-06

F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 11,313 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 3,423 RSUs that vest over three years, with 85% of such RSUs vesting on May 31, 2025 and 15% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock.

F6 · derivative.exercise_date: The canceled option was granted on February 7, 2018 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.

F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

Read SEC document
May 31, 2023 Filed Jun 2, 2023 20:00 UTC KALA BIO, Inc. KALA · Entity 7964 Disposition to issuerStock Option (right to buy) · Derivative 578 Not disclosed Strike: $750.00 Not disclosed
Disclosure

SEC source: 0001415889-23-009136 · form4-06022023_080614.xml · derivative · entry 3

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 578 shares

Expires 2027-07-18

F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 11,313 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 3,423 RSUs that vest over three years, with 85% of such RSUs vesting on May 31, 2025 and 15% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock.

F5 · derivative.exercise_date: The canceled option was granted on July 19, 2017 and provided for vesting over four years with 1/48th of the shares underlying the option vested on August 31, 2017 and an additional 1/48th of the shares vested at the end of each successive one-month period thereafter.

F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

Read SEC document
May 31, 2023 Filed Jun 2, 2023 20:00 UTC KALA BIO, Inc. KALA · Entity 7964 Disposition to issuerStock Option (right to buy) · Derivative 1,841 Not disclosed Strike: $167.00 Not disclosed
Disclosure

SEC source: 0001415889-23-009136 · form4-06022023_080614.xml · derivative · entry 2

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,841 shares

Expires 2025-06-17

F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 11,313 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 3,423 RSUs that vest over three years, with 85% of such RSUs vesting on May 31, 2025 and 15% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock.

F4 · derivative.exercise_date: The canceled option was granted on June 17, 2016 and provided for vesting over four years with 1/48th of the shares underlying the option vested on April 8, 2015 and an additional 1/48th of the shares vested at the end of each successive one-month period thereafter.

F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

Read SEC document
May 31, 2023 Filed Jun 2, 2023 20:00 UTC KALA BIO, Inc. KALA · Entity 7964 GrantCommon Stock 14,736 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-23-009136 · form4-06022023_080614.xml · nonDerivative · entry 1

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,619

F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 11,313 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 3,423 RSUs that vest over three years, with 85% of such RSUs vesting on May 31, 2025 and 15% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock.

F2 · balance_after: Includes 24,412 unvested RSUs.

Read SEC document
March 14, 2023 Filed Mar 15, 2023 20:00 UTC KALA BIO, Inc. KALA · Entity 7964 GrantStock Option (Right to Buy) · Derivative 432 $0.00 Strike: $68.50 $0.00
Disclosure

SEC source: 0001415889-23-004976 · form4-03152023_080310.xml · derivative · entry 1

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 432

Underlying: Common Stock · 432 shares

Expires 2032-01-03

F1 · derivative.exercise_date: On January 3, 2022, the Reporting Person was granted an option to purchase up to 1,620 shares of common stock of the Issuer. Specified portions of the options vest based on the level of achievement of specified performance metrics relating to financial, operational and scientific matters.

F2 · derivative.exercise_date: On March 14, 2023, the Compensation Committee of the Issuer's Board of Directors determined that certain of the performance conditions were achieved at specific levels of achievement, resulting in vesting of the option as to 432 shares of common stock. The Compensation Committee has made no determination with respect to certain performance metrics, which could result in the further vesting of up to 324 shares of common stock underlying the option.

Read SEC document
January 04, 2023 Filed Jan 6, 2023 20:00 UTC KALA BIO, Inc. KALA · Entity 7964 SaleCommon Stock 60 $28.54 $1,712.40
Disclosure

SEC source: 0001415889-23-000639 · form4-01062023_080117.xml · nonDerivative · entry 2

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,883

F3 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on January 4, 2021.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.52 to $28.71, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F5 · balance_after: Includes 9,676 unvested RSUs.

Read SEC document
January 04, 2023 Filed Jan 6, 2023 20:00 UTC KALA BIO, Inc. KALA · Entity 7964 GrantCommon Stock 9,525 $0.00 $0.00
Disclosure

SEC source: 0001415889-23-000639 · form4-01062023_080117.xml · nonDerivative · entry 1

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,943

F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2024, as to 1/3 of the shares underlying the RSUs on January 4, 2025 and as to the final 1/3 of shares underlying the RSUs on January 4, 2026.

F2 · balance_after: Includes 9,827 unvested RSUs.

Read SEC document
October 26, 2022 Filed Oct 28, 2022 16:15 UTC KALA BIO, Inc. KALA · Entity 7964 SaleCommon Stock 194 $6.51 $1,262.94
Disclosure

SEC source: 0001415889-22-010880 · form4-10282022_041020.xml · nonDerivative · entry 1

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,418

F1 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on June 25, 2020.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.51 to $6.56, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F3 · balance_after: Includes 302 unvested RSUs.

F4 · balance_after: The number of shares of common stock reported on this Form 4 reflects a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

Read SEC document
June 27, 2022 Filed Jun 29, 2022 20:12 UTC KALA BIO, Inc. KALA · Entity 7964 SaleCommon Stock 2,613 $0.37 $966.81
Disclosure

SEC source: 0001415889-22-007062 · form4-06292022_050657.xml · nonDerivative · entry 1

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,595

F1 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the reporting person's restricted stock units granted on June 25, 2020.

F2 · balance_after: Includes 45,611 unvested RSUs.

Read SEC document
January 04, 2022 Filed Jan 5, 2022 20:00 UTC KALA BIO, Inc. KALA · Entity 7964 SaleCommon Stock 2,850 $1.30 $3,705.00
Disclosure

SEC source: 0001415889-22-000405 · form4-01052022_080127.xml · nonDerivative · entry 1

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,208

F1 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units granted on January 4, 2021.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.25 to $1.39, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F3 · balance_after: Includes 53,611 unvested RSUs.

Read SEC document
January 03, 2022 Filed Jan 5, 2022 20:00 UTC KALA BIO, Inc. KALA · Entity 7964 GrantStock Option (right to buy) · Derivative 153,000 $0.00 Strike: $1.37 $0.00
Disclosure

SEC source: 0001415889-22-000405 · form4-01052022_080127.xml · derivative · entry 2

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,000

Underlying: Common Stock · 153,000 shares

Expires 2032-01-03

F4 · derivative.exercise_date: This option was granted on January 3, 2022 and vests with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.

Read SEC document
October 26, 2021 Filed Oct 28, 2021 20:04 UTC KALA BIO, Inc. KALA · Entity 7964 SaleCommon Stock 9,449 $1.80 $17,008.20
Disclosure

SEC source: 0001415889-21-005012 · form4-10282021_051034.xml · nonDerivative · entry 1

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,058

F1 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on June 25, 2020.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.89, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F3 · balance_after: Includes 61,166 unvested RSUs.

Read SEC document
June 28, 2021 Filed Jun 29, 2021 17:26 UTC KALA BIO, Inc. KALA · Entity 7964 SaleCommon Stock 2,452 $5.77 $14,148.04
Disclosure

SEC source: 0001415889-21-003259 · form4-06292021_050653.xml · nonDerivative · entry 1

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,507

F1 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the reporting person's restricted stock units granted on June 25, 2020.

F2 · balance_after: Includes 91,666 unvested RSUs.

Read SEC document
January 04, 2021 Filed Jan 5, 2021 16:48 UTC KALA BIO, Inc. KALA · Entity 7964 GrantStock Option (right to buy) · Derivative 90,667 $0.00 Strike: $6.86 $0.00
Disclosure

SEC source: 0001179110-21-000166 · edgar.xml · derivative · entry 2

Reumuth Mary · CIK 0001710969 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,667

Underlying: Common Stock · 90,667 shares

Expires 2031-01-03

F3 · derivative.exercise_date: This option was granted on January 4, 2021 and vests with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.

Read SEC document
January 04, 2021 Filed Jan 5, 2021 16:48 UTC KALA BIO, Inc. KALA · Entity 7964 GrantCommon Stock 22,666 $0.00 $0.00
Disclosure

SEC source: 0001179110-21-000166 · edgar.xml · nonDerivative · entry 1

Reumuth Mary · CIK 0001710969 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,959

F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2022, as to 1/3 of the shares underlying the RSUs on January 4, 2023 and as to the final 1/3 of shares underlying the RSUs on January 4, 2024.

F2 · balance_after: Includes 99,666 unvested RSUs.

Read SEC document
October 26, 2020 Filed Oct 28, 2020 20:22 UTC KALA BIO, Inc. KALA · Entity 7964 GrantCommon Stock 61,000 $0.00 $0.00
Disclosure

SEC source: 0001179110-20-010706 · edgar.xml · nonDerivative · entry 1

Reumuth Mary · CIK 0001710969 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,293

F1 · security: On June 25, 2020, the reporting person was granted performance-based restricted stock unit ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued employment with the Issuer, the RSUs will vest as to 50% of the shares underlying the RSUs on October 26, 2021, the first anniversary of the achievement of the performance condition, and as to the remaining 50% of the shares underlying the RSUs on October 26, 2022, the second anniversary of the achievement of the performance condition.

F2 · balance_after: Includes 77,000 unvested RSUs.

Read SEC document
June 25, 2020 Filed Jun 29, 2020 21:56 UTC KALA BIO, Inc. KALA · Entity 7964 GrantCommon Stock 16,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-20-078328 · a4.xml · nonDerivative · entry 1

Reumuth Mary · CIK 0001710969 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,293

F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued employment with the Issuer, the RSUs will vest as to 50% of the shares underlying the RSUs on June 25, 2021 and the remaining 50% of the shares underlying the RSUs on June 25, 2022.

F2 · balance_after: Includes 16,000 unvested RSUs.

Read SEC document
June 09, 2020 Filed Jun 11, 2020 16:58 UTC KALA BIO, Inc. KALA · Entity 7964 Exercise / conversionStock Option (right to buy) · Derivative 11,520 $0.00 Strike: $2.30 $0.00
Disclosure

SEC source: 0001179110-20-007239 · edgar.xml · derivative · entry 8

Reumuth Mary · CIK 0001710969 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,520 shares

Expires 2024-10-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option was fully vested.

Read SEC document
June 09, 2020 Filed Jun 11, 2020 16:58 UTC KALA BIO, Inc. KALA · Entity 7964 Exercise / conversionStock Option (right to buy) · Derivative 15,360 $0.00 Strike: $2.30 $0.00
Disclosure

SEC source: 0001179110-20-007239 · edgar.xml · derivative · entry 7

Reumuth Mary · CIK 0001710969 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,360 shares

Expires 2024-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option was fully vested.

Read SEC document
June 09, 2020 Filed Jun 11, 2020 16:58 UTC KALA BIO, Inc. KALA · Entity 7964 Exercise / conversionStock Option (right to buy) · Derivative 5,077 $0.00 Strike: $5.21 $0.00
Disclosure

SEC source: 0001179110-20-007239 · edgar.xml · derivative · entry 6

Reumuth Mary · CIK 0001710969 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,077 shares

Expires 2025-10-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option was fully vested.

Read SEC document
June 09, 2020 Filed Jun 11, 2020 16:58 UTC KALA BIO, Inc. KALA · Entity 7964 Exercise / conversionStock Option (right to buy) · Derivative 11,520 $0.00 Strike: $2.30 $0.00
Disclosure

SEC source: 0001179110-20-007239 · edgar.xml · derivative · entry 5

Reumuth Mary · CIK 0001710969 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,520 shares

Expires 2024-10-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option was fully vested.

Read SEC document
June 09, 2020 Filed Jun 11, 2020 16:58 UTC KALA BIO, Inc. KALA · Entity 7964 Exercise / conversionCommon Stock 11,520 $2.30 $26,496.00
Disclosure

SEC source: 0001179110-20-007239 · edgar.xml · nonDerivative · entry 4

Reumuth Mary · CIK 0001710969 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,293

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 09, 2020 Filed Jun 11, 2020 16:58 UTC KALA BIO, Inc. KALA · Entity 7964 Exercise / conversionCommon Stock 15,360 $2.30 $35,328.00
Disclosure

SEC source: 0001179110-20-007239 · edgar.xml · nonDerivative · entry 3

Reumuth Mary · CIK 0001710969 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,773

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 09, 2020 Filed Jun 11, 2020 16:58 UTC KALA BIO, Inc. KALA · Entity 7964 Exercise / conversionCommon Stock 5,077 $5.21 $26,451.17
Disclosure

SEC source: 0001179110-20-007239 · edgar.xml · nonDerivative · entry 2

Reumuth Mary · CIK 0001710969 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,413

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 09, 2020 Filed Jun 11, 2020 16:58 UTC KALA BIO, Inc. KALA · Entity 7964 Exercise / conversionCommon Stock 11,520 $2.30 $26,496.00
Disclosure

SEC source: 0001179110-20-007239 · edgar.xml · nonDerivative · entry 1

Reumuth Mary · CIK 0001710969 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,336

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 4,816 shares acquired under the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan on June 28, 2019.

Read SEC document
January 02, 2020 Filed Jan 3, 2020 16:11 UTC KALA BIO, Inc. KALA · Entity 7964 GrantStock Option (right to buy) · Derivative 120,000 $0.00 Strike: $3.84 $0.00
Disclosure

SEC source: 0001179110-20-000156 · edgar.xml · derivative · entry 1

Reumuth Mary · CIK 0001710969 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2030-01-01

F1 · derivative.exercise_date: This option was granted on January 2, 2020 and vests with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.

Read SEC document
January 02, 2019 Filed Jan 4, 2019 17:00 UTC KALA BIO, Inc. KALA · Entity 7964 GrantStock Option (right to buy) · Derivative 150,000 $0.00 Strike: $5.19 $0.00
Disclosure

SEC source: 0001179110-19-000455 · edgar.xml · derivative · entry 1

Reumuth Mary · CIK 0001710969 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2029-01-01

F1 · derivative.exercise_date: This option was granted on January 2, 2019 and vests with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.

Read SEC document
February 07, 2018 Filed Feb 9, 2018 16:30 UTC KALA BIO, Inc. KALA · Entity 7964 GrantStock Option (right to buy) · Derivative 70,000 $0.00 Strike: $12.86 $0.00
Disclosure

SEC source: 0001179110-18-001889 · edgar.xml · derivative · entry 1

Reumuth Mary · CIK 0001710969 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2028-02-06

F1 · derivative.exercise_date: This option was granted on February 7, 2018 and vests with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.

Read SEC document
July 19, 2017 Filed Jul 21, 2017 16:19 UTC KALA BIO, Inc. KALA · Entity 7964 GrantStock Option (right to buy) · Derivative 28,973 $0.00 Strike: $15.00 $0.00
Disclosure

SEC source: 0001179110-17-010591 · edgar.xml · derivative · entry 1

Reumuth Mary · CIK 0001710969 · Chief Financial Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,973

Underlying: Common Stock · 28,973 shares

Expires 2027-07-18

F1 · derivative.exercise_date: This option was granted, effective on July 19, 2017 and vests over four years, with 2.0833% of the shares underlying the option vesting on August 31, 2017 and an additional 2.0833% of the shares vesting at the end of each successive one-month period thereafter.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.